3 results
Approved WMOCompleted
The key objective of this study is to assess next-day residual effects of MK-4305 (20 and 40 mg) via driving performance after 1 day of dosing and after 8 days of dosing.
Approved WMOCompleted
The purpose of the study is to investigate how quickly and to what extent RO7033877 and CMS are getting into your blood stream and how long your body takes to get rid of it (this is called pharmacokinetics) when they are given alone or given at the…
Approved WMORecruiting
The purpose of this trial is to evaluate the safety and effectiveness of the Medtronic Evolut PRO+ and Evolut FX TAVR system and guideline-directed management and therapy (GDMT) compared to GDMT in patients with moderate, symptomatic AS. Data will…